RT Journal Article
SR Electronic
T1 Case finding of early pregnancies at risk of preeclampsia using maternal blood leptin/ceramide ratio
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.17.20248418
DO 10.1101/2020.12.17.20248418
A1 Huang, Qianyang
A1 Hao, Shiying
A1 You, Jin
A1 Yao, Xiaoming
A1 Li, Zhen
A1 Schilling, James
A1 Li, Zhen
A1 Thyparambil, Sheeno
A1 Liao, Wei-li
A1 Zhou, Xin
A1 Mo, Lihong
A1 Ladella, Subhashini
A1 Whitin, John C.
A1 Cohen, Harvey J.
A1 McElhinney, Doff B.
A1 Wong, Ronald J.
A1 Shaw, Gary M.
A1 Stevenson, David K.
A1 Sylvester, Karl G.
A1 Ling, Xuefeng B.
YR 2020
UL http://medrxiv.org/content/early/2020/12/19/2020.12.17.20248418.abstract
AB The early risk assessment of preeclampsia (PE) remains challenging in current clinical practice. We hypothesized that impending PE events can be predicted, when asymptomatic early in gestation, through the determination of the serum levels of leptin (Lep), a placental functions regulatory cytokine, and ceramide (Cer), a sphingolipid with anti-angiogenic and pro-apoptotic roles. Sera from two independent cohorts of PE and control women were assembled (Testing Cohort: 7 non-PE and 8 PE women sampled at confirmatory diagnoses; Validation Cohort: 20 non-PE and 20 PE women sampled longitudinally through gestation). Our multi-omics approach, integrating global genomic and lipidomic discoveries, revealed a marked elevation of the Lep/Cer (d18:1/25:0) ratio in PE women. Longitudinal analyses of Lep/Cer ratio can predict a median of 23 weeks before PE confirmative diagnosis. Sensitivity, positive predictive value, and AUC of the Lep/Cer (d18:1/25:0) ratio were 85%, 89%, and 0.92. Therefore, serum elevations of Lep/Cer (d18:1/25:0) ratio can be used to assess risk for impending PE during early asymptomatic pregnancies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approval was obtained from ProMedDX Inc. and the Institutional Review Board at Stanford University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed in this study are available upon request to the corresponding author.ACCAcetyl-CoA carboxylaseAUCArea Under the CurveAMPKK/AMPKAMP-activated protein kinaseBMIBody Mass IndexCPT1Carnitine Palmitoyltransferase 1CerCeramideCIConfidence IntervalDHCerDihydroceramideELISAEnzyme-Linked Immunosorbent AssayFAOFatty Acid OxidationGEOGene Expression OmnibusLepLeptinLetRLeptin ReceptorsLC/MS/MSLiquid Chromatography-Tandem Mass SpectrometryNPVNegative Predictive ValuePlGFPlacental Growth FactorPPVPositive Predictive ValuePEPreeclampsiasFlt-1Soluble fms-Like Tyrosine KinaseTGTriglycerideWkWeek